Lung Cancer Video Library - Spanish Language: Video #3 How does the NSCLC subtype (histology) alter chemotherapy recommendations in advanced NSCLC?

Video

For our third video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss how NSCLC subtype (histology) can alter chemotherapy recommendations in advanced NSCLC.

4 plus years stage 4 NSCLC with ALK mutation

Forums

New and first time post. Wife diagnosed nsclc 7/2012 stage 4 ALK mutation. Now 57 never smoker and active exerciser. Full 6 treatments carbo/alimta and 1plus year alimta maintenance. Crizotinib about a year forced to ceritinib due to more than 25 brain mets and balnce issues. also at same time, whole brain radiation in 10/2015 mistake??? Brain mets size reduced and stable as of 6/2016. Was it radiation or ceritinib?? Bone mets in shoulder 2/2016 and palliative rad.

How do we manage a "mixed response" to lung cancer treatment?

Article

Here's a brief video that explains my approach to a so-called "mixed response" to treatment for a lung cancer.  

[powerpress]

There isn't a formal teaching or "best answer" about how to approach this issue, but what I explain here is a common and I think very sensible strategy for a still controversial clinical setting (if I do say so myself).  I'd welcome your comments.

I hope you find it helpful if you or someone you care about faces this situation.

A Case of a 36 Year-Old Never-Smoking Woman with Metastatic Adenocarcinoma of the lung

Article

With all this recent talk about never-smokers with lung cancer, and the interest in stories of patients with so-called “oligometastatic” cancer (minimal metastatic burden to perhaps a single site), I thought I would describe a recent case in my clinic as an illustration of how I use this information in everyday decision making.

The Subtleties of Progressive Disease: Why Some Oncologists Continue EGFR Inhibitors (or Other Agents) after Progression

Article

One of the basic concepts of oncology is that you treat patients with different drugs once they've shown progression on a treatment, rather than continue that a patient has presumably become resistant to. However, there are some exceptions to this: many or most women with breast cancer continue the antibody herceptin (trastuzumab) even after progression, adding it to one chemo and then the next, and the same is often done with avastin in colon cancer and sometimes lung cancer as well.

A New Look at Maintenance Treatment after First-Line Chemotherapy in NSCLC

Article

With the recent publication of the Eli Lilly-sponsored phase III trial of immediate versus delayed Taxotere (docetaxel) after the completion of first-line chemotherapy in patients with advanced NSCLC (abstract of paper by Fidias and colleagues here), I think the time has come to critically evaluate this as a potentially practice-changing concept.

Tarceva Dose Escalation in Current Smokers: Could Higher Doses Improve Results?

Article

We have long noted that there is a clear association of smoking history with effectiveness of oral EGFR tyrosine kinase inhibitors (TKIs). Part of this is because never-smokers have a high incidence of carrying activating EGFR mutations, but also potentially because current smokers actually metabolize EGFR TKIs faster (see prior post).

ATLAS: Another Trial Shows Benefit for "Maintenance"/Early Second Line Therapy

Article

A press release today informs us that the ATLAS trial of maintenance avastin (bevacizumab) combined with tarceva (erlotinib) vs. avastin with placebo was positive for a significant improvement in progression-free survival (PFS). We had already learned that the very similar SATURN, of maintenance tarceva vs.